Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Exclusion Criteria

• •Smoking
• •Diabetes type 1 or 2, as defined by a fasting glucose of 126 mg/dl or greater or the use of anti-diabetic medication
• •Hypertension as defined by an untreated seated SBP greater than 140 mmHg an untreated DBP greater than 90 mmHg or the use of antihypertensives
• •History of reported or recorded hypoglycemia (plasma glucose less than 70 mg/dl)
• •Pregnancy
• •Breast-feeding
• •Use of hormone replacement therapy
• •The use of contraceptive therapy
• •Use of any medication other than multivitamin
• •Hematocrit \<35%
• •Cardiovascular disease such as history of myocardial infarction, presence of angina pectoris, significant arrhythmia, congestive heart failure(LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy
• •Asthma
• •History of angioedema
• •History of cough or other side effect during ACE inhibitor use
• •Impaired renal function, as defined by an eGFR\<60ml/min/1.73M2
• •Clinically significant gastrointestinal impairment that could interfere with drug absorption
• •Impaired hepatic function (aspartate amino transaminase\[AST\] and/or alanine amino transferase \[ALT\]\>2 x upper limit of normal range
• •History of alcohol or drug abuse
• •Treatment with any investigational drug in the 1 month preceding the study
• •Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study
• •Inability to comply with the protocol, e.g., uncooperative attitude, inability to return to follow-up visits, and the unlikelihood of completing the study